Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) reported Q2 2017 earnings this Morning, coming in at ($0.33) per share, beating Wall Street’s estimates of ($0.44) per Share. Revenue for the quarter came in at $12.00 million missing the streets estimates of $18.34 million
Analyst Coverage For Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
These are 1 Hold Rating, 5 Buy Ratings .
The current consensus rating for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) is Buy (Score: 2.83) with a consensus target price of $28.00 , a potential (71.78% upside)Recent Insider Trading for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)
- On 6/6/2016 James F Tessmer, VP, sold 1,500 with an average share price of $15.00 per share and the total transaction amounting to $22,500.00.
- On 5/23/2016 James F Tessmer, VP, sold 6,000 with an average share price of $13.00 per share and the total transaction amounting to $78,000.00.
- On 12/12/2014 C.V. Invus, Director, bought 150,000 with an average share price of $0.88 per share and the total transaction amounting to $132,000.00.
- On 12/10/2014 C.V. Invus, Director, bought 315,896 with an average share price of $0.90 per share and the total transaction amounting to $284,306.40.
- On 11/26/2014 International S.C.A. Artal, Director, bought 149,253,731 with an average share price of $1.01 per share and the total transaction amounting to $150,746,268.31.
- On 10/23/2012 International S.C.A. Artal, Director, bought 3,000,000 with an average share price of $2.25 per share and the total transaction amounting to $6,750,000.00.
Recent Trading for Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX) Shares of Lexicon Pharmaceuticals, Inc. closed the previous trading session at 15.79 down -0.51 -3.13% with 734,671 shares trading hands.